Результаты поиска

What Are the Peripheral Blood Determinants for Increased Osteoclast Formation in the Various Inflammatory Diseases Associated With Bone Loss?

Local priming of osteoclast precursors (OCp) has long been considered the main and obvious pathway that takes place in the human body, where local bone lining cells and RANKL-expressing osteocytes may facilitate the differentiation of OCp. However, priming of OCp away from bone, such as in inflammatory tissues, as revealed in peripheral blood, may represent a second pathway, particularly relevant in individuals who suffer from systemic bone loss such as prevalent in inflammatory diseases. In this review, we used a systematic approach to review the literature on osteoclast formation in peripher

Совпадение в полном тексте источника
… Infliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis. (2008) 67:620–4. 10.1136/ard.2007.076711 48. Vandooren B, Melis L, Veys EM, Tak PP, Baeten D. … Tumor necrosis factor-alpha antagonist infliximab inhibits osteoclast formation of peripheral blood mononuclear cells but does not affect periodontal ligament fibroblast-mediated osteoclast formation. J Periodontal Res. (2016) 51:186–95. 10.1111/jre.12297 52. …

Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander".

Targeted immune checkpoint blockade augments anti-tumor immunity and induces durable responses in patients with melanoma and other solid tumors. It also induces specific "immune-related adverse events" (irAEs). IrAEs mainly include gastrointestinal, dermatological, hepatic and endocrinological toxicities. Off-target effects that arise appear to account for much of the toxicity of the immune checkpoint blockade. These unique "innocent bystander" effects are likely a direct result of breaking immune tolerance upon immune check point blockade and require specific treatment guidelines that include

Совпадение в полном тексте источника
… If symptoms persist despite high-dose steroids or are refractory to steroid tapering, other immunosuppressive treatments may be necessary, such as infliximab for severe enterocolitis [ 85 ]. … Ipilimumab-induced acute severe colitis treated by infliximab Melanoma Res. 2013 23 227 230 10.1097/CMR.0b013e32835fb524 23458760 87. …

Drug Repurposing for the Management of Depression: Where Do We Stand Currently?

A slow rate of new drug discovery and higher costs of new drug development attracted the attention of scientists and physicians for the repurposing and repositioning of old medications. Experimental studies and off-label use of drugs have helped drive data for further studies of approving these medications. A deeper understanding of the pathogenesis of depression encourages novel discoveries through drug repurposing and drug repositioning to treat depression. In addition to reducing neurotransmitters like epinephrine and serotonin, other mechanisms such as inflammation, insufficient blood supp

Совпадение в полном тексте источника
… Postherpetic neuralgia, seizures | Modulates the release of excitatory neurotransmitters which participate in epileptogenesis and nociception/Anticonvulsant, GABA analog | NA | >10%: dizziness, drowsiness, ataxia, fatigue, viral infections | Hypersensitivity to gabapentin or any component of the formulation Infliximab … Infliximab (Including Biosimilars of Infliximab): Drug Information. [(accessed on 4 June 2021)]; Available online: https://uptodatefree.ir/topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information . 70. Ketamine: Drug Information. …

Antibody and aptamer-based therapies for osteoarthritis: Application of antibodies and promise of aptamers.

Osteoarthritis (OA) is a common degenerative inflammatory joint disease with progressive loss of articular cartilage that undermines patients' quality of life. There are no regulatory-approved, disease-modifying OA medications, despite a great deal of studies done to elucidate OA pathogenesis. Until now, OA pharmacological treatment focused mainly on generalized inhibition of inflammation and pain. Currently, monoclonal antibodies and nucleic-acid aptamers emerge as targeted therapies offering potential alternatives by addressing the complex challenges posed by OA, such as specifically reducin

Совпадение в полном тексте источника
… efficacy of infliximab were further evaluated in a phase 4, unbalanced, randomized, double-blind pilot study ( NCT01144143 ) for the treatment of knee OA. … Nanocomposites-based targeted oral drug delivery systems with infliximab in a murine colitis model J. Nanobiotechnol. 18 2020 133 10.1186/s12951-020-00693-4 PMC7493402 32933548 77 Zhang Q. Lv H.h. Chen A. Liu F. Wu X. Efficacy of infliximab in a rabbit model of osteoarthritis Connect. …

Molecular therapeutic strategies targeting pancreatic cancer induced cachexia.

Pancreatic cancer (PC) induced cachexia is a complex metabolic syndrome associated with significantly increased morbidity and mortality and reduced quality of life. The pathophysiology of cachexia is complex and poorly understood. Many molecular signaling pathways are involved in PC and cachexia. Though our understanding of cancer cachexia is growing, therapeutic options remain limited. Thus, further discovery and investigation of the molecular signaling pathways involved in the pathophysiology of cachexia can be applied to development of targeted therapies. This review focuses on three main p

Совпадение в полном тексте источника
… In phase II clinical trials, adjunct infliximab to standard gemcitabine therapy showed no significant change in lean body mass, performance status, or survival[ 58 , 59 ]. … A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. J Support Oncol. 2008;6:18–25. 59. Centocor, Inc. …

Inflammatory Manifestations, Therapeutic Interventions, and Cancer Risk in Psoriasis: Current Epidemiological and Mechanistic Evidence.

Psoriasis is a chronic, autoimmune skin disease driven by persistent inflammation and immune dysfunction that severely impairs quality of life and is associated with serious comorbidities, including psoriatic arthritis, cardiovascular diseases (CVDs), and depression. Emerging epidemiological evidence suggests an association between psoriasis and an increased risk of certain malignancies, such as breast cancer (BC) and non-Hodgkin's lymphoma (NHL), although the strength and consistency of these associations vary across study designs, and the underlying thrombo-inflammatory mechanisms remain inc

Совпадение в полном тексте источника
… Prominent therapeutic agents within this classification include etanercept, infliximab, and adalimumab. … A notable exception is infliximab, which demonstrates a more rapid onset of action, with clinical responses observed by weeks 8 to 10. However, the sustained neutralization of systemic TNF-α is associated with severe class-specific adverse effects. …

The Risk of Sarcoidosis Misdiagnosis and the Harmful Effect of Corticosteroids When the Disease Picture Is Incomplete.

Sarcoidosis is a complex granulomatous disease of unknown etiology. Due to the heterogeneity of the disease, the diagnosis remains challenging in many cases, often at the physician's discretion, requiring a thorough and complex investigation. Many other granulomatous diseases have the potential to mimic sarcoidosis, whether infectious, occupational, or autoimmune diseases and starting an unnecessary corticosteroid treatment can worsen the patient's prognosis, leading to side effects that can be harder to treat than the actual disease.

Совпадение в полном тексте источника
… A case report by Thaniyavarn T. showcased the case of a 47-year-old man who was diagnosed with pulmonary sarcoidosis and was under treatment with infliximab. … Third-line agents for pulmonary sarcoidosis include infliximab and adalimumab [ 43 ]. …

Использование биологов во время беременности среди пациентов с аутоиммунными условиями.

ВАЖНОСТЬ: Продолжение биологики у пациентов с аутоиммунным заболеванием, которые забеременеют, связано с взвешиванием последствий связанных с беременностью изменений степени серьезности заболеваний и потенциального тератогенного воздействия лекарств. Характеристика методов биологического лечения во время беременности может дать представление о рисках и выгодах, связанных с материнством и зародышом. ЦЕЛЬ: Описание схемы использования биологов у беременных с аутоиммунными заболеваниями. DESIGN, SETTING И УЧАСТНИКИ: В этом когортном исследовании использовались данные научно-исследовательских баз

Совпадение в полном тексте источника
… In patients with inflammatory bowel disease (ulcerative colitis or Crohn disease), TNF inhibitors are recommended during pregnancy, with final doses administered several half-lives before the expected delivery date. 22 For rheumatologic conditions, patients taking adalimumab, infliximab, and golimumab … In individuals with inflammatory bowel disease, discontinuation of adalimumab 48 and infliximab 49 during pregnancy has been associated with the risk for flares, which are associated with premature deliveries. …

VEXAS Syndrome: A Comprehensive Review of Current Therapeutic Strategies and Emerging Treatments.

VEXAS syndrome is a recently identified autoinflammatory disorder resulting from somatic mutations in the UBA1 gene, leading to a complex spectrum of severe inflammatory and hematologic manifestations. The absence of established treatment guidelines and the variability in clinical presentation make its management particularly challenging. Current therapeutic approaches are often based on limited evidence, and their effectiveness remains inconsistent. This review seeks to consolidate the existing knowledge on therapeutic strategies for VEXAS syndrome, offering a critical evaluation of their eff

Совпадение в полном тексте источника
… In a systematic review, four patients received TNF inhibitors alongside corticosteroids: one with etanercept, one with infliximab, one with infliximab combined with methotrexate, and one with adalimumab combined with methotrexate. … Furthermore, in a Canadian cohort, two patients were treated with infliximab and etanercept in combination with other medications. Infliximab demonstrated a lack of efficacy and was discontinued due to the incidental discovery of rectal cancer. …

Time-dependent clearance can confound exposure-response analysis of therapeutic antibodies: A comprehensive review of the current literature.

Exposure-response (ER) analysis is used to optimize dose and dose regimens during clinical development. Characterization of relationships between drug exposure and efficacy or safety outcomes can be utilized to make dose adjustments that improve patient response. Therapeutic antibodies typically show predictable pharmacokinetics (PK) but can exhibit clearance that decreases over time due to treatment. Moreover, time-dependent changes in clearance are frequently associated with drug response, with larger decreases in clearance and increased exposure seen in patients who respond to treatment. Th

Совпадение в полном тексте источника
… biosimilar (CT‐P13) | TNFα | CD, UC | ID | No | Time‐varying covariates | CL | NA | NA | Disease activity | 92 Infliximab | TNFα | CD, UC | ID | No | Linear increase | CL | +13%/year | NA | Unstated | 93 Infliximab | TNFα | UC | ID | No | Post hoc | CL | 22% | NR | Unstated | 42 Certolizumab pegol | … Population pharmacokinetics of subcutaneous infliximab CT‐P13 in Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther. 2021;54:1309‐1319. 93. Petitcollin A, Brochard C, Siproudhis L, et al. …

Ход работы сессии 31st Европейский педиатрический конгресс по педиатрии: часть 2.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Results: Thirty-four patients, for a total of 85 samples (median age: 11 y, 24 female, median dose: 0.34 mg/kg, median therapy duration: 13 months, 51 on biological cotreatment (22 adalimumab, 11 infliximab and 18 other) were enrolled. …

Estimating the shares of the value of branded pharmaceuticals accruing to manufacturers and to patients served by health systems.

Previous studies have estimated that patients served by health systems accrue 59-98% of the value generated by new pharmaceuticals. This has led to questions about whether sufficient returns accrue to manufacturers to incentivize socially optimal levels of R&D. These studies have not, however, fully reflected the health opportunity costs imposed by payments for branded pharmaceuticals. We present a framework for estimating how the value generated by new branded pharmaceuticals is shared. We quantify value in net health effects and account for benefits and health opportunity costs in the patent

Совпадение в полном тексте источника
… Infliximab for the treatment of adults with psoriasis. https://www.nice.org.uk/guidance/ta134 National Institute for Health and Care Excellence . (2010a). … Infliximab and adalimumab for the treatment of Crohn's disease. https://www.nice.org.uk/guidance/ta187 National Institute for Health and Care Excellence . (2013). …

UEG Week 2015 Poster Presentations

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Advances in drug therapy for systemic lupus erythematosus.

Systemic lupus erythematosus (SLE) is an autoimmune disorder that afflicts 500,000 people in the United States. There has not been a new SLE drug approved in the United States since 1958. However, a guidance document issued by the Food and Drug Administration in 2005 provided a roadmap for investigators which spawned numerous ongoing clinical trials. Among these, Belimumab, a monoclonal antibody to soluble B lymphocyte stimulator, met its primary endpoints in two large trials and will probably obtain FDA approval soon. Other promising agents targeting a variety of mechanisms of action are curr

Совпадение в полном тексте источника
… Only infliximab has been studied to any extent in pure SLE. Synovitis can be helped, but extra-articular manifestations may worsen and anti-DNA, anticardiolipin levels can appear or increase. … Hough D Cooper SM Freimuth W Petri M Belimumab A BLyS specific inhibitor, reduced disease activity and severe flares with seropositive SLE: BLISS-76 study Lupus 2010 19S 13 Aringer M Houssiau F Gordon C Graninger WB Voll RE Rath E Steiner G Smolen JS Adverse events and efficacy of TNF-α blockade with infliximab …

The Role of Angiogenesis in Haemophilic Arthropathy: Where Do We Stand and Where Are We Going?

Haemophilia is an inherited bleeding disorder that can lead to degenerative joint arthropathy due to recurrent bleeding episodes affecting the musculoskeletal system of the patient. The cause of bleeding can be either traumatic or spontaneous. The pathogenesis of haemophilic arthropathy is unclear as many factors like iron, inflammatory cytokines, and angiogenic factors contribute to this process. Blood into joints can deteriorate the bone to such an extent that the patient experiences pain, reduction of the range of movement, and deformity of the joint, conditions that could have a great impa

Совпадение в полном тексте источника
… Infliximab treatment in combination with methotrexate reduced synovial VEGF expression and vascularity [ 36 , 37 ]. Anti-TNF therapy in arthritic patients reduced Ang-1 but stimulated Ang-2 expression [ 38 ]. … therapy: a prospective single-centre study Arthritis Res Ther 2004 6 326 334 10.1186/ar1182 PMC464872 15225368 38 Markham T Mullan R Golden-Mason L Rogers S Bresnihan B Fitzgerald O Fearon U Veale DJ Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab …

Recent advances in the management of systemic lupus erythematosus.

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease presenting highly heterogeneous clinical manifestations and multi-systemic involvement. Patients are susceptible to relapse- and remission, thus making management challenging. Moreover, a considerable number of side effects may occur with conventional therapies; therefore, there is clearly a need for new therapeutic strategies. Since the pathogenesis of SLE is highly complex, it is far from being fully understood. However, greater understanding of the pathways and of the cellular and molecular mediators involved in SLE is being

Совпадение в полном тексте источника
… Infliximab. Infliximab is a human-murine chimeric mAb directed against TNF-α 109 . … Changes M: Infliximab (remicade) anti-TNF. Interactions. 1998;50:1–25. 110. TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL). Full Text View - ClinicalTrials.gov. Reference Source 111. …

Elevated serum globulin fraction as a biomarker of multiyear disease severity in inflammatory bowel disease.

BackgroundSerum protein reflects albumin and globulin levels, both of which can be altered in inflammatory bowel disease (IBD). The implications of a high globulin fraction in IBD are unknown. We hypothesized that a high globulin fraction may function independently of albumin as a biomarker of disease severity in IBD patients over a multiyear period.MethodsThis was an observational study from a prospective IBD registry of a tertiary care center. High globulin fraction was defined as an elevated globulin level >4 g/dL. Data collected included patient demographics, medication exposures, quality-

Совпадение в полном тексте источника
… Biologics included anti-tumor necrosis factor medications (infliximab, adalimumab, certolizumab pegol). Finally, 5-aminosalicylic acid compounds included sulfasalazine, mesalamine, balsalazide, either oral or topical. … B-cell dysregulation in Crohn's disease is partially restored with infliximab therapy. PLoS One. 2016;11:e0160103. doi: 10.1371/journal.pone.0160103. 23. Wang X, Jiang Y, Zhu Y, et al. …

The Rationale for Using Neridronate in Musculoskeletal Disorders: From Metabolic Bone Diseases to Musculoskeletal Pain.

Neridronate or ((6-amino-1-hydroxy-1-phosphonohexyl) phosphonic acid) is an amino-bisphosphonate (BP) synthetized in Italy in 1986. Bisphosphonates are molecules with a P-C-P bond in their structure that allows strong and selectively binding to hydroxyapatite (HAP) as well as osteoclasts inhibition through different mechanisms of action. Neridronate was initially used to treat Paget disease of the bone, demonstrating effectiveness in reducing bone turnover markers as well as pain. The interesting molecular properties of neridronate foster its wide use in several other conditions, such as osteo

Совпадение в полном тексте источника
… Many years later, monthly IV neridronate (100 mg) was compared to infliximab (mg/kg) to investigate the anti-inflammatory and bone metabolic effects of these interventions in patients with ankylosing spondylitis (AS) [ 74 ]. … Viapiana et al. [ 74 ] | Open label study | AS | IV (100 mg monthly) | 60 | Benefits in terms of reduced disease activity comparable to infliximab. BMD improvements in the short term (3–6 months). …

Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study.

Background: It is now recognized that psoriasis plays a key role in the development of several comorbidities, such as cardiovascular disease, and metabolic syndrome. Some authors have hypothesized that patients with psoriasis may have an increased risk of developing certain types of cancer. The efficacy and safety of biologic drugs are well-documented in clinical trials and in real-life studies. However, there is limited evidence on the safety of the use of biologic treatments in cancer patients with psoriasis, and the use of this therapeutic class in patients with a pre-existing or concomitan

Совпадение в полном тексте источника
… In severe or refractory psoriasis, guidelines recommend using biological therapies directed against TNF-alpha (adalimumab, etanercept, certolizumab, infliximab) or the IL-23/17 axis (ustekinumab, guselkumab, risankizumab, tildrakizumab, brodalumab, ixekizumab, secukinumab, bimekizumab) [ 18 , 19 ]. … The search terms ‘psoriasis’ were combined using the Boolean operator ‘AND’ with ‘adalimumab’, ‘etanercept’, ‘infliximab’, ‘certolizumab’, ‘secukinumab’, ‘ixekizumab’, ‘brodalumab’, ‘bimekizumab’, ‘guselkumab’, ‘tildrakizumab’, and ‘risankizumab’. …

An Integrated Health-System Specialty Pharmacy Model for Coordinating Transitions of Care: Specialty Medication Challenges and Specialty Pharmacist Opportunities.

Adherence and persistence to specialty medications are necessary to achieve successful outcomes of costly therapies. The increasing use of specialty medications has exposed several unique barriers to certain specialty treatments' continuation. Integrated specialty pharmacy teams facilitate transitions in sites of care, between different provider types, among prescribed specialty medications, and during financial coverage changes. We review obstacles encountered within these types of transitions and the role of the specialty pharmacist in overcoming these obstacles. Case examples for each type

Совпадение в полном тексте источника
… For example, if a patient is initiated on infliximab while inpatient, the hospital formulary can mandate a biosimilar, such as Inflectra ® (infliximab), be administered to the patient for the first induction dose. … Once discharged, the patient’s insurance could require the patient to switch to Remicade ® (infliximab). While these are both versions of infliximab, no studies have validated the efficacy of switching products during the induction phase. …